By designing wearable devices in new ways, Wearifi is a technology company seeking to create epidermal electronics with all of the performance of the current state of the art at a fraction of the size. Our mission is to devise the next generation of electronic solutions – integrated, invisible when you want them to be, and battery-free – to personal healthcare that promote positive feedback between cognitive science and precision medicine.
Wearifi has partnered with multiple Fortune 500 companies, the Department of Health and Human Services, and leading research hospitals to drive personalized healthcare management with wearable electronic gadgets. The core technology represents not only the outcome of research efforts from Querrey Simpson Institute for Bioelectronics at Northwestern University but continuous interactions with the research/clinical teams to develop engineering solutions that are capable of non-invasively skin health monitoring, motion envelope visualization, haptic feedback for VR/AR and prosthetic applications, in-real time. At Wearifi, you’ll have an opportunity to work in a collaborative environment that leads to academic publications and technology innovations, so together we can engineer the future of smart healthcare.
 

Taboola helps people find relevant content online, matching them with news stories, articles, blogs, videos, apps, products and other content they’re likely to want to explore.
How do we know what they’ll like? Using machine-learning algorithms, our technology analyzes hundreds of signals to capture exactly what kind of content is most likely to engage each individual. We do that more than 450 billion times a month for more than one billion unique users.

Since we opened our doors in 2006, we have grown to become the leading discovery platform on the open web, serving a combination of the world’s best brands and the most respected global publishers.

Taboola is headquartered in New York City with local offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Istanbul, Seoul, Sydney and Tokyo.

CytoLumina Technologies Corp. is dedicated to expanding precision medicine through the development of nanotechnology-enabled rare-cell capture and sorting platforms. The company is focused on making dramatic improvements in patient quality of life by developing assays that capture rare circulating tumor cells (CTCs) from a standard blood sample.

mFluiDx is aiming to develop the ultra-low cost, automated point-of-care DNA diagnostic assay for small clinics. In small clinics, such as primary care out-patient clinics, disease diagnosis is typically done by observing symptoms or using paper-strip antibody tests. However, these methods have poor sensitivity compared to DNA diagnostics.  Highly sensitive molecular DNA tests (PCR) are not often used because of cost and the need to send tests off-site resulting in a slow turnaround time (several days).

mFluiDx is a UC Berkeley spinoff startup developing Gates Foundation funded low-cost microfluidic diagnostic technologies capable of on-site multi-target isothermal DNA detection of infectious diseases with simple operation and ~100X lower cost than PCR setups. We aim to create assays that can be deployed in decentralized settings, are as simple and cheap as paper tests, yet have DNA level sensitivity for onsite diagnosis.

mFluiDx has been selected as one of the top 20 finalists from a global competition of 900 startups at Techcrunch’s Startup Battlefield, it has participated the world’s leading biotech startup accelerator (Indiebio Accelerator). It was selected as top 6 early stage startups among all 10 UC campuses. It ranked top 3% among America’s biotech grant applicants. We look forward to work with trainees that can work with us long term and is excited in joining mFluiDx’s vision for next generation diagnostics. 

More info can be found in this video link (CITRIS Foundry demo day pitch): https://youtu.be/WSEKyGikUKU